Marksans Pharma share news, announcements and annual reports
NSE: MARKSANSBSE: 524404Pharmaceuticals & BiotechnologySmall Cap
Marksans Pharma Limited · Formerly Tasc Pharmaceuticals · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 1994 on BSE, Jan 2002 on NSE
Last close ₹315.35up ₹10.15 (3.33%)BSE ₹315.10
Share price at the NSE close on 29 Oct 2026. Previous close ₹305.20.
29 Oct: open ₹305.90, high ₹318.80, low ₹300.00
52-week range of traded prices to 29 Oct 2026
₹155.00Low, 30 Mar 2026₹350.95High, 24 Sep 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹14,291 Cr592nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 27.65
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.73
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.29%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record.
- 17.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 19.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.01
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 20,08,91538.7% delivered
Marksans Pharma share news and announcements
683 announcements, routine notices left out, newest first. Page 12 of 14.
Feb 2014
Jan 2014
20 Jan · Board meeting
To consider and approve Unaudited Financial Results of the Company for the quarter ended December 31, 2013.
Nov 2013
Oct 2013
31 Oct · Management
Board of Directors of the Company at its meeting held on October 31, 2013, appointed Mr. Naresh Balwant Wadhwa as an additional Director of the Company. Mr. Wadhwa will be an independent non-executive director.21 Oct · Board meeting
To consider and approve Unaudited Financial Results of the Company for the Quarter ended September 30, 2013.
Sep 2013
30 Sep · Disclosure of Voting Pattern - Clause 35A
26 Sep · Management
Mr.Seetharama Raju Buddharaju who was appointed a Director of the Company in the casual vacancy caused by the resignation of Mr. M.B. Parikh, has ceased to be a Director as such effective from the date of the Annual General Meeting September 26, 2013. Further, be informed that the Shareholders have, at the Annual General Meeting held on September 26, 2013, appointed Mr. Seetharama Raju Buddharaju as a Director of the Company liable to retire by rotation with effect from September 26, 2013.4 Sep · Corporate action
Company has fixed Book Closure from September 21, 2013 to September 26, 2013 for the purpose of Annual General Meeting.
Jul 2013
22 Jul · Updates
Marksans Pharma Limited had informed the Exchange that the Company was registered with BIFR under SICA. The Company has informed the Exchange that the Company has been de-registered from the purview of SICA and is no longer in BIFR as per the directions of the Hon'ble BIFR in its hearing held on July 17, 2013. The summary record of proceedings of the hearing is awaited.22 Jul · Board meeting
To consider and approve Unaudited Financial Results of the Company for the Quarter ended June 30, 2013.
May 2013
20 May · Board meeting
To consider and approve Annual Audited Financial Results of the Company for the financial year ended on March 31, 2013.
Mar 2013
4 Mar · Updates
Company has entered into a Settlement Agreement with the holders of Foreign Currency Convertible Bonds (FCCBs) for settling USD 26,918,000 worth of FCCBs in principal value.
Feb 2013
5 Feb · Board meeting
To consider and approve Unaudited Financial Results of the Company for the Quarter ended on December 31, 2012.
Dec 2012
17 Dec · Board meeting
10 Dec · Board meeting
To consider conversion of warrants and issue and allot in lieu thereof 1,75,00,000 Equity Shares of Re.1/- each to Mr. Mark Saldanha,Promoter of the Company on preferential allotment basis.
Nov 2012
1 Nov · Board meeting
To consider and approve Unaudited Financial Results of the Company for the Quarter ended on September 30, 2012.
Oct 2012
Sep 2012
27 Sep · Management
Mr. Ajay S. Joshi, who was appointed a Director of the Company in the casual vacancy caused by the resignation of Mr. Kumar Nair, has ceased to be a Director as such effective from the date of the Annual General Meeting held on September 27, 2012. Further, the Company has at the Annual General Meeting held on September 27, 2012 appointed Mr. Ajay S. Joshi as a Director of the Company liable to retire by rotation with effect from September 27, 2012.8 Sep · Meeting
Company has announced the book closure from September 22, 2012 to September 27, 2012 (both days inclusive) for the purpose of Annual General Meeting of the Company scheduled to be held on September 27, 2012.
Aug 2012
3 Aug · Board meeting
To consider and approve Unaudited Financial Results of the Company for the Quarter ended June 30, 2012.
May 2012
29 May · Results
18 May · Board meeting
To consider and approve Annual Audited Financial Results for the financial year ended on March 31, 2012.
Apr 2012
27 Apr · Results
Company will publish Annual Audited Results for the entire financial year ended March 31, 2012 before May 30, 2012. Therefore, unaudited financial results for the quarter ended March 31, 2012 will not be published.
Feb 2012
1 Feb · Board meeting
To consider and approve Unaudited Financial Results for the Quarter ended on December 31, 2011.
Nov 2011
2 Nov · Board meeting
To consider and approve Unaudited Financial Results for the Quarter ended on September 30, 2011.
Oct 2011
5 Oct · Management
Mr. M.B Parikh has resigned as a Director of the Company with effect from October 5, 2011.The Board of Directors of the Company has at its Meeting held on October 5, 2011, appointed Mr. Seetharama Raju Buddharaju as a Director of the Company to fill the casual vacancy caused by the resignation of Mr. M.B. Parikh.
Aug 2011
26 Aug · Meeting
Company has announced the book closure from September 24, 2011 to September 29, 2011 (both days inclusive) for the purpose of Annual General Meeting of the Company scheduled to be held on September 29, 2011.26 Aug · Board meeting
In order to strengthen the capital base of the Company, the Board of Directors of the Company at its meeting held August 26, 2011, has proposed to issue, subject to the approval of the shareholders and the regulatory authority as applicable 1,75,00,000 (One crore seventy five lacs only) warrants convertible into equal numbers of equity shares of Re. 1/- each to the Promoters of the Company under private placement basis at such price and under the terms and conditions in accordance with Chapter VII of the SEBI (ICDR) Regulations, 2009 as in force.2 Aug · Board meeting
To consider and approve Unaudited Financial Results for the quarter ended June 30, 2011.
Jul 2011
15 Jul · Management
Mr. V. Nagaraj has resigned as Director and Whole-time Director of the Company with effect from June 29, 2011.
Jun 2011
20 Jun · Board meeting
To consider and approve Consolidated Annual Audited Financial Results of the Company for the Financial Year ended on March 31, 2011.
May 2011
28 May · Results
18 May · Board meeting
Company had informed the Exchange that a meeting of the Board of Directors of the Company will be held on May 20, 2011 to consider and approve Audited Financial Results of the Company for the Financial Year ended on March 31, 2011. The Company has now informed the Exchange that the aforesaid meeting of the Board of Directors of the Company is rescheduled to be held on May 28, 2011 (instead May 20,2011 as intimated earlier) to consider and approve Audited Financial Results of the Company for the Financial Year ended on March 31, 2011.Not held on this date
12 May · Board meeting
To consider and approve Audited Financial Results of the Company for the Financial Year ended on March 31, 2011.